DR. DREAM

DR-18 to Prevent or Treat Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapse After Hematopoietic Cell Transplantation, the DR. DREAM Trial

Not Evaluated

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1
Enrollment
40 patients (estimated)
Sponsors
Fred Hutchinson Cancer Research Center
Collaborators
Simcha Therapeutics
Tags
Interleukin 18 (IL-18)
Trial Type
Treatment
Last Update
SparkCures ID
1967
NCT Identifier
NCT06492707

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print this trial to share with your doctor.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.